Glioma Imaging

Glioma Imaging

  • Whitney B. Pope
Publisher:Springer NatureISBN 13: 9783030273590ISBN 10: 3030273598

Paperback & Hardcover deals ―

Amazon IndiaGOFlipkart GOSnapdealGOSapnaOnlineGOJain Book AgencyGOBooks Wagon₹9,515Book ChorGOCrosswordGODC BooksGO

e-book & Audiobook deals ―

Amazon India GOGoogle Play Books ₹69.42Audible GO

* Price may vary from time to time.

* GO = We're not able to fetch the price (please check manually visiting the website).

Know about the book -

Glioma Imaging is written by Whitney B. Pope and published by Springer Nature. It's available with International Standard Book Number or ISBN identification 3030273598 (ISBN 10) and 9783030273590 (ISBN 13).

This book covers physiologic, metabolic and molecular imaging for gliomas. Gliomas are the most common primary brain tumors. Imaging is critical for glioma management because of its ability to noninvasively define the anatomic location and extent of disease. While conventional MRI is used to guide current treatments, multiple studies suggest molecular features of gliomas may be identified with noninvasive imaging, including physiologic MRI and amino acid positron emission tomography (PET). These advanced imaging techniques have the promise to help elucidate underlying tumor biology and provide important information that could be integrated into routine clinical practice. The text outlines current clinical practice including common scenarios in which imaging interpretation impacts patient management. Gaps in knowledge and potential areas of advancement based on the application of more experimental imaging techniques will be discussed. In reviewing this book, readers will learn: current standard imaging methodologies used in clinical practice for patients undergoing treatment for glioma and the implications of emerging treatment modalities including immunotherapy the theoretical basis for advanced imaging techniques including diffusion and perfusion MRI, MR spectroscopy, CEST and amino acid PET the relationship between imaging and molecular/genomic glioma features incorporated in the WHO 2016 classification update and the potential application of machine learning about the recently adopted and FDA approved standard brain tumor protocol for multicenter drug trials of the gaps in knowledge that impede optimal patient management and the cutting edge imaging techniques that could address these deficits